Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference
EQS Group-News: Polyphor AG / Key word(s): Study/Study results
Allschwil, Switzerland, March 23rd, 2018
The open label study recruited 56 patients with metastatic breast cancer who had previously received one to three chemotherapeutic regimes. Patients received increasing doses of balixafortide (0.5 - 5.5 mg/kg) alongside eribulin. An expanded cohort received the combination of eribulin and the recommended Phase II tolerated dose of balixafortide.
In the expanded cohort (n=24), balixafortide combined with eribulin showed a 63% Clinical Benefit Rate (CBR) and a 38% Overall Response Rate (ORR)[i]. The safety and tolerability of the combination appeared comparable to published data on either eribulin or balixafortide monotherapy.
"We believe the data presented today show balixafortide to be the first CXCR4 inhibitor to demonstrate proof of concept in solid tumors," said Dr. Debra Barker, Chief Medical and Development Officer of Polyphor. "This trial underlines the potential of balixafortide to provide a new treatment option for patients with late stage HER2 negative breast cancer where there remains a significant unmet medical need. Following our recent end of Phase I meeting with the U.S. Food and Drug Administration (FDA), we have identified specific next steps towards a pivotal trial to potentially support registration for balixafortide in the U.S. and look forward to advancing this clinical program."
For further information please contact:
Document title: Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference